Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study

BACKGROUND: Patients with multiple sclerosis (MS) often receive disease-modifying therapies (DMTs) that can expose them to reactivation of potential occult hepatitis B virus (HBV) infection (pOBI). We aimed to evaluate the MS Centers behavior regarding HBV screening and prophylaxis in a large cohort...

Descripción completa

Detalles Bibliográficos
Autores principales: Buonomo, Antonio Riccardo, Viceconte, Giulio, Calabrese, Massimiliano, De Luca, Giovanna, Tomassini, Valentina, Cavalla, Paola, Maniscalco, Giorgia Teresa, Ferraro, Diana, Nociti, Viviana, Radaelli, Marta, Buscarinu, Maria Chiara, Paolicelli, Damiano, Gajofatto, Alberto, Annovazzi, Pietro, Pinardi, Federica, Di Filippo, Massimiliano, Cordioli, Cinzia, Zappulo, Emanuela, Scotto, Riccardo, Gentile, Ivan, Spiezia, Antonio Luca, Petruzzo, Martina, De Angelis, Marcello, Brescia Morra, Vincenzo, Solaro, Claudio, Gasperini, Claudio, Cocco, Eleonora, Moccia, Marcello, Lanzillo, Roberta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9119877/
https://www.ncbi.nlm.nih.gov/pubmed/35165767
http://dx.doi.org/10.1007/s00415-022-11009-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9119877/
https://www.ncbi.nlm.nih.gov/pubmed/35165767
http://dx.doi.org/10.1007/s00415-022-11009-x

Ejemplares similares